Twist Bioscience ( (TWST) ) has shared an update.
On May 2, 2025, Twist Bioscience Corporation completed a Contribution Agreement with Atlas Data Storage, Inc., securing $155 million in investments by spinning out its DNA data storage product group into an independent company, Atlas Data Storage. This strategic move allows Twist to focus on its core operations while maintaining a stake in the new entity, benefiting from future milestones and royalties. Twist reported record revenue of $92.8 million for the second quarter of fiscal 2025, marking a 23% increase from the previous year, and improved its gross margin to 49.6%. The company expects to achieve adjusted EBITDA breakeven by the end of fiscal 2026, driven by continued growth and innovation.
Spark’s Take on TWST Stock
According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.
Twist Bioscience shows strong revenue growth but is hindered by profitability and cash flow challenges. The technical outlook is neutral, and the negative P/E ratio highlights valuation concerns. While recent earnings and corporate events provide some optimism, significant operational improvements are needed for a more favorable outlook.
To see Spark’s full report on TWST stock, click here.
More about Twist Bioscience
Twist Bioscience Corporation is a mid-cap growth and value equity company operating in the life sciences segment of the healthcare sector. The company focuses on developing and commercializing disruptive products and services, primarily in synthetic biology, next-generation sequencing, and biopharma sectors.
YTD Price Performance: -13.40%
Average Trading Volume: 1,181,465
Technical Sentiment Signal: Buy
Current Market Cap: $2.34B
See more data about TWST stock on TipRanks’ Stock Analysis page.